Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.41 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.41 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | FES | P07332 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8408666 | 0.86 | ITGB3 (0.47) | FOLH1MAPTEPHX2 | |
| SCHEMBL6358943 | 0.85 | FOLH1 (0.48) | FOLH1MAPTPTAFRCYP3A4EPHX2 | |
| SCHEMBL6954777 | 0.84 | FOLH1 (0.47) | FOLH1MAPTPTAFRCYP3A4EPHX2 | |
| SCHEMBL29538593 | 0.80 | GPR132 (0.50) | FOLH1CYP3A4GPR132CMKLR2CMKLR1 | |
| SCHEMBL4924076 | 0.78 | ITGB3 (0.56) | PTAFR | |
| SCHEMBL243189 | 0.78 | PTAFR (0.41) | MAPTPTAFRCYP3A4EPHX2 | |
| SCHEMBL6946884 | 0.78 | ITGB3 (0.55) | MAPTCYP3A4 | |
| SCHEMBL8410736 | 0.77 | MAPT (0.43) | FOLH1MAPTPTAFRCYP3A4FAAH | |
| SCHEMBL12205313 | 0.76 | MME (0.51) | — | |
| SCHEMBL3300590 | 0.75 | NPY4R (0.57) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | FOLH1 2015/4885MAPT 4206/4885PTAFR 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.